Coherus, In Ring As A Biosimilar Contender, Hopes To Smack Down Humira
Executive Summary
Six-year-old biosimilar specialist could be first company to launch a biosimilar version of Neulasta, but the possibility of a biosimilar version of Humira has investors ogling.
You may also be interested in...
Coherus Knocks Out One Humira Patent But Others Block Biosimilars
Patent Trial and Appeal Board invalidates patent on method to treat rheumatoid arthritis; next hurdle is overcoming formulation patents that do not expire until 2022.
Coherus Knocks Out One Humira Patent But Others Block Biosimilars
Patent Trial and Appeal Board invalidates patent on method to treat rheumatoid arthritis; next hurdle is overcoming formulation patents that do not expire until 2022.
Can Biosimilar Studies Be Conducted Solely In Healthy Volunteers?
Coherus refutes Apotex argument that Neulasta biosimilars must be studied in at least one patient population. Its application could face delay as no advisory committee meeting has been scheduled ahead of its June 9 user fee date.